オンキュア・セラピューティクス
OnKure Therapeutics, Inc.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.31 | $0 | -$10M |
| 2026 Q1 | -1.11 | $0 | -$13M |
| 2025 Q4 | -0.99 | $0 | -$12M |
| 2025 Q3 | -1.09 | $0 | -$13M |
| 2025 Q2 | -1.14 | $0 | -$13M |
| 2025 Q1 | -1.19 | $0 | -$14M |
| 2024 Q4 |
| -2.64 |
| $0 |
| -$21M |
| 2024 Q3 | -0.28 | $0 | -$11M |